tirofiban has been researched along with Hemorrhage in 112 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (8.04) | 18.2507 |
2000's | 46 (41.07) | 29.6817 |
2010's | 43 (38.39) | 24.3611 |
2020's | 14 (12.50) | 2.80 |
Authors | Studies |
---|---|
Bian, Z; Cao, C; Ding, X; Feng, S; Kong, Y; Li, H; Li, Y; Li, Z; Oscar, B; Pan, C; Wang, W; Xie, Z; Zhao, L | 1 |
Dong, H; Hu, X; Lin, Y; Wang, W; Ye, J; Yu, B; Zhou, L; Zhou, Y | 1 |
Beaujeux, R; Chibbaro, S; Gheoca, R; Hasiu, A; Mangin, PH; Mihoc, D; Pop, R; Quenardelle, V; Severac, F; Simu, M; Tudor, R; Wolff, V | 1 |
Alyan, Ö; Er, A; Gürdal, A; Keskin, K; Kilci, H; Ser, ÖS; Sığırcı, S; Sümerkan, MÇ | 1 |
Esposito, G; Ettori, F; Ferlini, M; Lettieri, C; Marchese, A; Musumeci, G; Passamonti, E; Pierini, S; Rigattieri, S; Romano, M; Tarantini, G; Testa, L; Tiberti, G | 1 |
Chilbert, MR; Denny, O; Mills, K; Woodruff, AE | 1 |
Emani, SM; Piekarski, BL; Rogers, J; Thiagarajan, R; Zurakowski, D | 1 |
Adar, A; Akbay, E; Akıncı, S; Çoner, A; Müderrisoğlu, H | 1 |
Li, R; Tang, X; Zhang, T | 1 |
Gao, C; Han, X; Mitchell, MJ; Nie, G; Wang, C; Wang, K; Xu, J; Yan, N; Yang, C; Zhang, Y | 1 |
Ding, J; Huang, S; Ji, X; Lian, Y; Ma, Q; Ren, M; Song, H; Sun, C; Wang, L; Wang, Y; Wu, C; Wu, D; Xie, N; Zhao, W | 1 |
Adair, BD; Ahn, HS; Alonso, JL; Arnaout, MA; Hayes, V; Lin, SW; Poncz, M; van Agthoven, J; Xiong, JP; Yu, IS | 1 |
Huang, S; Li, X; Liang, C; Liu, C; Wang, H; Zhang, M | 1 |
Fu, Z; Gao, L; Liu, X; Wang, Z; Xu, C | 1 |
Degrauwe, S; Iglesias, JF; Laurencet, ME; Noble, S; Tessitore, E | 1 |
Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y | 1 |
Adina, Q; Bildirici, U; Celikyurt, U; Dervis, E; Ural, D; Yavuz, S | 1 |
Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
Chourdakis, E; Hahalis, G; Koniari, I; Kounis, NG; Patsouras, N; Roumeliotis, A; Soufras, G; Tsigkas, G | 1 |
Gao, D; Hu, S; Li, H; Li, M; Wang, H; Zhang, H; Zhu, J | 1 |
Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Levkau, B; Mourikis, P; Naguib, D; Pöhl, M; Polzin, A; Schulze, V; Wolff, G; Zako, S; Zeus, T | 1 |
Anderson, GL; Barsness, GW; Bell, MR; Mara, KC; Nei, SD; Osborn, JL; Ou, NN | 1 |
Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S | 1 |
Gao, C; Hu, D; Li, M; Liu, H; Wang, X; Yang, H; Zhang, Y; Zhu, Z | 1 |
Chen, Y; Chi, Y; Liu, C; Song, L; Wang, J; Wang, S; Yan, H; Zhao, B; Zhao, H; Zhou, P | 1 |
Xie, Q; Zhang, J; Zhang, T; Zhu, J | 1 |
Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO | 1 |
Francis, PK; Gupta, PN; Shylaja, SV; Thomas, J | 1 |
Adiyaman, A; Giannitsis, E; Hamm, C; Hoorntje, JC; Schellings, DA; Suryapranata, H; Ten Berg, JM; Van't Hof, AW | 1 |
Ding, FH; Du, R; Hu, J; Liao, ML; Shen, WF; Wang, XL; Yang, ZK; Zhang, JS; Zhang, Q; Zhang, RY; Zhu, TQ | 1 |
Chen, J; Chen, S; Guo, J; Han, Y; Jiang, D; Jiang, T; Jing, Q; Li, J; Li, Y; Liang, Z; Liu, H; Stone, GW; Su, X; Wang, Y; Xu, B; Yang, P; Zang, H; Zhao, X; Zheng, Y | 1 |
Dondurmacı, E; Sağ Ertürk, F; Şarlı, B; Tok, A; Uğurlu, M | 1 |
Han, Y; Li, Y; Liang, Z; Liu, H; Ma, L; Stone, GW; Wang, D; Wang, J; Wang, S; Yang, L | 1 |
Huang, H; Ouyang, F; Peng, H; Yin, Y; Zeng, J; Zhou, X | 1 |
Chen, SL; Chen, YD; Chen, YG; Cheng, XS; Ge, JB; Han, YL; Jiang, TM; Li, JL; Li, Y; Liang, ZY; Liu, HW; Liu, ML; Ma, LK; Ma, YT; Wang, G; Wang, HY; Xie, Q; Yang, BS; Zhao, X; Zheng, XQ | 1 |
Fu, Q; Huang, YJ; Qiu, CR; Tao, ZQ; Wei, P; Yang, XJ; Zhang, Q; Zhang, YG; Zuo, XH | 1 |
Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S | 1 |
Borklu, EB; Cinier, G; Eren, M; Hayiroglu, MI; Kaya, A; Keskin, M; Tatlisu, MA; Uzman, O | 1 |
Bao, D; Chen, Y; Cong, H; Ding, S; Han, Y; Jia, S; Jing, Q; Li, J; Li, L; Li, Y; Liang, Z; Liu, B; Liu, H; Wang, H; Zhao, X | 1 |
Chaudhary, HT | 1 |
Cao, Y; Ding, X; Gamariel, RR; Kong, Y; Li, ZY; Liu, TD; Liu, XD; Ming, X; Wang, CH; Xie, ZL; Zhao, Q | 1 |
Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q | 1 |
Cavusoglu, E; Lazar, J; Marmur, JD; Poludasu, S | 1 |
Zijlstra, F | 1 |
Chen, LL; Li, WW; Lin, YL; Luo, YK; Zheng, XC | 1 |
Jia, D; Li, Y; Nie, X; Yan, Z; Zhao, Y; Zhou, Y; Zhou, Z | 1 |
De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW | 1 |
Biondi-Zoccai, G; Bolognese, L; Briguori, C; Campo, G; Danzi, GB; Hamm, C; King, SB; Moliterno, DJ; Okmen, E; Saia, F; Tebaldi, M; ten Berg, J; Topol, EJ; Valgimigli, M; van't Hof, AW | 1 |
Briguori, C; Caccavale, M; D'Andrea, D; Focaccio, A; Golia, B; Librera, M; Ricciarelli, B; Tavano, D; Visconti, G | 1 |
Bates, ER; Chetcuti, S; Grossman, PM; Gurm, HS; Meier, P; Tamhane, U | 1 |
Agnelli, D; Al-Kayyali, S | 1 |
Juwana, YB; Ottervanger, JP; Suryapranata, H; van 't Hof, AW | 1 |
Doraiswamy, VA | 1 |
Tebaldi, M; Valgimigli, M | 1 |
Birhan Yilmaz, M; Caldir, V; Refiker Ege, M | 1 |
Dambrink, JH; Dill, T; Hamm, C; Hermanides, RS; Kolkman, E; Ottervanger, JP; Ten Berg, JM; van 't Hof, AW; van Houwelingen, G | 1 |
Moliterno, DJ | 1 |
Armstrong, PW; Bolognese, L; Braunwald, E; Califf, RM; Durand, E; Giugliano, RP; Harrington, RA; Hasselblad, V; Kong, DF; Moliterno, DJ; Newby, LK; Prabhakaran, D; Rasoul, S; Stone, GW; Théroux, P; Tricoci, P; Van de Werf, F; White, HD | 1 |
Eisenberg, MJ; Friedland, S; Shimony, A | 1 |
Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G | 1 |
Guo, J; Xi, Y; Xu, M | 1 |
Akpınar, TS; Besısık, SK; Elcioglu, OC; Ozkok, A; Sezer, M; Tufan, F; Umman, S | 1 |
Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Wang, X; Wang, Y; Wu, W; Xue, H; Yang, Z; Zhao, Y | 1 |
Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD | 1 |
Alpert, JS; Antman, EM; Beasley, JW; Braunwald, E; Califf, RM; Cheitlin, MD; Faxon, DP; Fuster, V; Gibbons, RJ; Gregoratos, G; Hiratzka, LF; Hochman, JS; Jacobs, AK; Jones, RH; Kereiakes, D; Kupersmith, J; Levin, TN; Pepine, CJ; Schaeffer, JW; Smith, EE; Smith, SC; Steward, DE; Theroux, P | 1 |
DiBattiste, PM; Jang, Ik; Januzzi, JL; Sabatine, MS; Servoss, SJ; Theroux, P; Wan, Y | 1 |
Tsakiris, DA | 1 |
Ali, A; Gardin, JM; Hashem, M; Kazmouz, G; Rosman, HS; Schrieber, TL | 1 |
Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Lorenz, DP; Marble, SJ; Murphy, SA; Pinto, DS | 1 |
Brown, DL | 1 |
Alemao, E; Bakhai, A; Ben-Joseph, R; Collinson, JR; Flather, MD; Itzler, R; Normand, C; Stevens, W | 1 |
Antman, EM; Bates, ER; Cohen, M; Every, NR; Ferguson, JJ; Harrington, RA; Pepine, CJ; Theroux, P | 1 |
Akin, Y; Biyikoglu, SF; Guray, U; Korkmaz, S; Yilmaz, MB | 1 |
Gill, DS; Ng, K; Ng, KS | 1 |
Ardissino, D; Brennan, DM; Buratti, S; Menozzi, A; Merlini, PA; Moliterno, DJ; Rossi, M; Topol, EJ | 1 |
Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD | 1 |
Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
Brouse, SD; Wiesehan, VG | 1 |
Graf, C; Nkoulou, R; Perrenoud, JJ; Trombert, V | 1 |
Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH | 1 |
DiBattiste, PM; Huynh, T; Pharand, C; Piazza, N; Snapinn, SM; Theroux, P; Wan, Y | 1 |
Berger, PB; Best, PJ; Chan, AW; DiBattiste, PM; Herrmann, HC; Kristensen, SD; Moliterno, DJ; Topol, EJ; White, J | 1 |
Chen, SM; Fang, CY; Fu, M; Guo, GB; Hsieh, YK; Wu, CJ; Yip, HK | 1 |
Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB | 1 |
Delgado, C; Fernández-Perez, GC; Rodríguez-Pérez, J; Vázquez, M; Vázquez-Lima, A; Velasco, M | 1 |
Banerjee, S; Chen, S; Ho, C; Labinaz, M; Martin, J; Mensinkai, S | 1 |
Anderson, KM; Coller, BS; Weisman, HF | 1 |
Anderson, HL; Edmunds, LH; Gikakis, N; Gorman, JH; Gould, RJ; Hiramatsu, Y; Marcinkiewicz, C; Niewiarowski, S | 1 |
Al-Mousa, EN; Arshad, MN; Campsey, M; Gandhi, R; Gibson, CM; Marble, SJ; Mattson, S; Mesley, R; Moynihan, JL; Murphy, S; Ryan, KA; Swanson, J | 1 |
Juran, NB | 1 |
Dyke, CM | 1 |
Tcheng, JE | 1 |
Califf, RM; Lincoff, AM; Topol, EJ | 1 |
Blankenship, JC; Dasgupta, H; Demko, SL; Frey, CM; Menapace, FJ; Wood, GC | 1 |
Jang, IK; Sabatine, MS | 1 |
Mak, KH; Moliterno, DJ | 1 |
Berkowitz, SD | 1 |
Vernon, SM | 1 |
Bertrand, M; Cohen, DJ; Cohen, EA; Demopoulos, L; DiBattiste, PM; Grines, CL; Herrmann, HC; Moliterno, DJ; Neumann, FJ; Powers, ER; Stone, GW; Topol, EJ | 1 |
Kurz, HI; Lasala, JM; Taniuchi, M | 1 |
Bertel, O; Genoni, M; Maloigne, M; Turina, M; Zeller, D | 1 |
Corno, A; Horisberger, J; Marty, B; Mueller, X; von Segesser, LK | 1 |
Becker, RC; Denier, D; Gouveia, W; Kimmelstiel, C; MacIsaac, DA; Miele, R; Phang, R; Rand, W; Rehman, A; Rhofiry, J | 1 |
Banaszewski, M; Konopka, A; Stepinska, J; Szajewski, T | 1 |
Kondo, K; Umemura, K | 1 |
DiBattiste, PM; Jang, IK; Januzzi, JL; Snapinn, SM; Theroux, P | 1 |
Cucchiara, BL; Hurst, RW; Liebeskind, DS; McGarvey, ML; Pollard, JR; Schwartz, ED | 1 |
25 review(s) available for tirofiban and Hemorrhage
Article | Year |
---|---|
Safety and Efficacy of Tirofiban in Acute Ischemic Stroke Patients Receiving Endovascular Treatment: A Meta-Analysis.
Topics: Brain Ischemia; Endovascular Procedures; Hemorrhage; Humans; Patient Safety; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Time Factors; Tirofiban; Treatment Outcome | 2020 |
+Ophitoxaemia and myocardial infarction--the issues during primary angioplasty: a review.
Topics: Angioplasty; Animals; Antivenins; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Bites; Snake Venoms; Snakes; Tirofiban; Tyrosine | 2014 |
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Chemotherapy, Adjuvant; Hemorrhage; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Regression Analysis; Tirofiban; Tyrosine | 2010 |
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Tirofiban for myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Double-Blind Method; Drug Resistance; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Multicenter Studies as Topic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Topics: Acetates; Acute Coronary Syndrome; Administration, Cutaneous; Angioplasty; Electrocardiography; Eptifibatide; Hemorrhage; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Tirofiban; Tyrosine | 2011 |
Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Circulation; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2011 |
Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Fatal Outcome; Female; Hemorrhage; Humans; Lung Diseases; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tirofiban; Tyrosine | 2012 |
Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Hemorrhage; Humans; Male; Middle Aged; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Thrombocytopenia; Tirofiban; Tyrosine | 2012 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Bleeding Time; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Reoperation; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Thrombosis; Tirofiban; Tyrosine | 1996 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Catheterization, Peripheral; Coronary Disease; Coronary Thrombosis; Eptifibatide; Femoral Artery; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Safety; Tirofiban; Tyrosine | 1999 |
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
Topics: Eptifibatide; Hemorrhage; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; Survival Rate; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes.
Topics: Acetates; Acute Disease; Eptifibatide; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Tirofiban; Tyrosine | 1999 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Nadroparin; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Thrombosis; Tirofiban; Transaminases; Tyrosine | 2001 |
Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
Topics: Abciximab; Ancrod; Antibodies, Monoclonal; Anticoagulants; Arginine; Cardiopulmonary Bypass; Chondroitin Sulfates; Cross Reactions; Dermatan Sulfate; Drug Combinations; Drug Hypersensitivity; Factor Xa Inhibitors; Hemodilution; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudin Therapy; Humans; Immunoglobulin Fab Fragments; Perfusion; Pipecolic Acids; Platelet Aggregation Inhibitors; Protamines; Sulfonamides; Thrombocytopenia; Thrombophilia; Thrombosis; Tirofiban; Tyrosine | 2001 |
Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2002 |
35 trial(s) available for tirofiban and Hemorrhage
Article | Year |
---|---|
Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Topics: Anterior Wall Myocardial Infarction; Arrhythmias, Cardiac; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Drug Administration Schedule; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Complications; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Impact of selective infarct-related artery infusion of tirofiban on myocardial reperfusion and bleeding complications in patients with acute myocardial infarction: the SUIT-AMI trial.
Topics: Aged; Cardiac Catheterization; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Prospective Studies; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
Topics: Aged; Area Under Curve; Biomarkers; Decision Support Techniques; Female; Hemorrhage; Humans; Length of Stay; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Patient Discharge; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
Topics: Aged; Biomarkers; Chi-Square Distribution; China; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Creatine Kinase, MB Form; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Prosthesis Design; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Up-Regulation | 2015 |
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Topics: Aged; Antithrombins; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Tirofiban; Tyrosine | 2015 |
The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
Topics: Aged; Anticoagulants; Antithrombins; Chi-Square Distribution; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Emergency Treatment; Female; Hemorrhage; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Protective Factors; Recombinant Proteins; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Clinical effects of treatment with Tirofiban on patients with high-risk NSTE-ACS after PCI.
Topics: Acute Coronary Syndrome; Adult; Aged; Creatine Kinase, MB Form; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cardiac Catheterization; China; Emergencies; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radial Artery; Recombinant Proteins; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Warfarin; Young Adult | 2017 |
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Vessels; Drug Administration Routes; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2009 |
Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Heart Diseases; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Thrombocytopenia; Time Factors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Retreatment; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
Risk of bleeding after prehospital administration of high dose tirofiban for ST elevation myocardial infarction.
Topics: Aged; Emergency Medical Services; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors; Single-Blind Method; Tirofiban; Tyrosine | 2012 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Retrospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Aged; Chi-Square Distribution; China; Coronary Angiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
Topics: Aged; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Patient Admission; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Syndrome; Tirofiban; Treatment Outcome; Tyrosine; United Kingdom | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Transfusion; Combined Modality Therapy; Coronary Stenosis; Double-Blind Method; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Stents; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Topics: Acute Disease; Aged; Coronary Disease; Dalteparin; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Stenosis; Creatinine; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention.
Topics: Aged; Angiography; Angioplasty, Balloon, Coronary; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Thrombosis; Double-Blind Method; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIb-IX Complex; Postoperative Complications; Retreatment; Time Factors; Tirofiban; Tyrosine | 1997 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; Exanthema; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Neutropenia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS
Topics: Acute Disease; Aged; Coronary Artery Disease; Creatinine; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Assessment; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
53 other study(ies) available for tirofiban and Hemorrhage
Article | Year |
---|---|
Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.
Topics: Drug Design; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propionates; Thrombosis | 2017 |
Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
Topics: Aged; China; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome | 2021 |
Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; Thrombectomy; Tirofiban; Treatment Outcome | 2023 |
In-Hospital Bleeding in Elderly Patients With Acute Coronary Syndrome: Are Potent Antiplatelet Agents Safe?
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Female; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry.
Topics: Aged; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Reperfusion; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Cohort Studies; Fibrinolytic Agents; Hemorrhage; Humans; Integrin alpha2; Integrin beta3; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Thrombosis; Tirofiban; Treatment Outcome | 2022 |
In-Hospital Bleeding and Mortality in Acute Coronary Syndrome Patients Treated with Tirofiban and Potent P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents.
Topics: Animals; Blood Platelets; Hemorrhage; Mice; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Tirofiban | 2023 |
Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome After Intravenous Thrombolysis.
Topics: Aged; Disease Progression; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Mortality; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome | 2019 |
Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis.
Topics: Animals; Blood Coagulation; Disease Models, Animal; Drug Design; Gene Knock-In Techniques; Healthy Volunteers; Hemorrhage; Humans; K562 Cells; Male; Mice; Mice, Transgenic; Peptides; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Structure-Activity Relationship; Thrombosis; Tirofiban; von Willebrand Factor | 2020 |
Effects of Oral Antiplatelet Agents and Tirofiban on Functional Outcomes of Patients with Non-Disabling Minor Acute Ischemic Stroke.
Topics: Administration, Intravenous; Administration, Oral; Aged; Brain Ischemia; Disability Evaluation; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recovery of Function; Retrospective Studies; Risk Factors; Stroke; Time Factors; Tirofiban; Treatment Outcome | 2020 |
Walking on a thin line between potent platelet inhibition for myocardial infarction and risk of hemorrhagic complications. Tirofiban induced subconjunctival hemorrhage.
Topics: Adult; Blood Platelets; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine; Walking | 2021 |
Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Dual Anti-Platelet Therapy; Female; Functional Status; Hemorrhage; Humans; Infusions, Intravenous; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Recovery of Function; Retrospective Studies; Time Factors; Tirofiban; Treatment Outcome | 2021 |
Early Thrombosuction and Tirofiban Use in Knee and Below-Knee Arterial Thrombosis.
Topics: Aged; Aged, 80 and over; Arteries; Embolism; Female; Hemorrhage; Humans; Knee Joint; Leg; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombectomy; Thromboembolism; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Perioperative Management of Dual Antiplatelet Therapy.
Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Tirofiban; Tyrosine | 2018 |
Effect of intra-coronary administration of tirofiban through aspiration catheter on patients over 60 years with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon, Coronary; Catheters; Drug Administration Routes; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardium; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2018 |
Safety and efficacy of Tirofiban in STEMI-patients.
Topics: Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Germany; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Comparison of In-Hospital Bleeding and Cardiovascular Events with High-Dose Bolus Tirofiban and Shortened Infusion to Short-Duration Eptifibatide as Adjunctive Therapy for Percutaneous Coronary Intervention.
Topics: Aged; Eptifibatide; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Monitoring; Electrocardiography; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Effects of upstream administration of tirofiban before percutaneous coronary intervention on spontaneous reperfusion and clinical outcomes in acute ST-segment elevation myocardial infarction.
Topics: Aged; Chi-Square Distribution; Combined Modality Therapy; Coronary Circulation; Disease-Free Survival; Drug Administration Schedule; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrhage; Humans; Italy; Myocardial Ischemia; Peptides; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Societies, Medical; Stents; Surgical Procedures, Operative; Thoracic Surgery; Ticlopidine; Tirofiban; Tyrosine | 2014 |
A misleading diagnosis in acute coronary syndrome: tirofiban-induced alveolar hemorrhage.
Topics: Acute Coronary Syndrome; Acute Lung Injury; Adult; Diagnostic Errors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Tirofiban; Tyrosine | 2015 |
Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia.
Topics: Aged; Coronary Occlusion; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Thrombocytopenia; Tirofiban; Tyrosine | 2016 |
[A large-scale, multicenter, retrospective study on efficacy of bivalirudin use during peri-percutaneous coronary intervention period for Chinese patients with coronary heart disease].
Topics: Aged; China; Coronary Disease; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; Stroke; Tirofiban; Tyrosine | 2016 |
The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
Topics: Aged; Cause of Death; Coronary Thrombosis; Female; Hemorrhage; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
In-Silico Analysis of Amotosalen Hydrochloride Binding to CD-61 of Platelets.
Topics: Bleeding Time; Blood Platelets; Computer Simulation; Furocoumarins; Hemorrhage; Humans; Photosensitizing Agents; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2016 |
A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin
Topics: Abciximab; Animals; Antibodies, Monoclonal; Cardiovascular Diseases; Disease Models, Animal; Eptifibatide; Fibrinogen; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Integrin alpha2; Integrin beta3; Mice; Naphthalenes; Peptides; Platelet Aggregation; Rats; Thrombocytopenia; Thrombosis; Tirofiban; Tyrosine | 2016 |
Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Alveolar hemorrhage following tirofiban treatment. A misleading diagnosis.
Topics: Aged; Diagnostic Errors; Female; Hemorrhage; Humans; Lung Diseases; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Tirofiban; Tyrosine | 2010 |
Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring
Topics: Anticoagulants; Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Double-Blind Method; Drug Resistance; Elective Surgical Procedures; Hemorrhage; Heparin; Humans; Myocardial Revascularization; Patient Selection; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Research Design; Thromboembolism; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Alveolar hemorrhage following tirofiban treatment. A misleading diagnosis.
Topics: Hemorrhage; Humans; Lung Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Pulmonary Wedge Pressure; Tirofiban; Tyrosine | 2010 |
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clopidogrel; Disease Management; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Health Behavior; Hemorrhage; Humans; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2002 |
Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Linear Models; Logistic Models; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Factors; Safety; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Lung Diseases; Male; Michigan; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Wedge Pressure; Tirofiban; Treatment Failure; Tyrosine; Ventricular Pressure | 2003 |
Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).
Topics: Angioplasty, Balloon, Coronary; Blood Coagulation Tests; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Tirofiban; Tyrosine | 2003 |
Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Death, Sudden; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Tyrosine | 2003 |
Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication.
Topics: Coronary Stenosis; Fatal Outcome; Female; Hemorrhage; Humans; Lung Diseases; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2004 |
Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.
Topics: Angina, Unstable; Diagnostic Errors; Fatal Outcome; Hemorrhage; Humans; Lung Diseases; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Edema; Radiography; Tirofiban; Tyrosine | 2004 |
Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Hospitals, Veterans; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Regression Analysis; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine | 2004 |
Safety of tirofiban therapy in very old patients with acute coronary syndrome or non-Q-wave myocardial infarction.
Topics: Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine | 2005 |
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
Topics: Aged; Angina, Unstable; Anticoagulants; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Syndrome; Tirofiban; Tyrosine | 2005 |
Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Topics: Acute Disease; Adult; Angina, Unstable; Blood Transfusion; Cerebral Hemorrhage; Creatinine; Disease Susceptibility; Dose-Response Relationship, Drug; Eptifibatide; Glomerular Filtration Rate; Hemorrhage; Hemorrhagic Disorders; Humans; Kidney Diseases; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Registries; Sex Characteristics; Tirofiban; Tyrosine | 2006 |
Pulmonary hemorrhage in a patient with acute coronary syndrome.
Topics: Aged; Angina, Unstable; Hemorrhage; Humans; Lung Diseases; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Tirofiban; Tyrosine | 2007 |
Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons.
Topics: Animals; Bleeding Time; Cardiopulmonary Bypass; Hemodynamics; Hemorrhage; Heparin; Papio; Platelet Aggregation Inhibitors; Platelet Count; Postoperative Complications; Tirofiban; Tyrosine | 1997 |
Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Premedication; Syndrome; Tirofiban; Tyrosine | 1998 |
Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery.
Topics: Blood Coagulation; Blood Transfusion; Coronary Disease; Drug Administration Schedule; Drug Monitoring; Emergencies; Hemorrhage; Humans; Infusions, Intravenous; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Creatine Kinase; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Retrospective Studies; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
Topics: Anticoagulants; Coronary Stenosis; Drug Therapy, Combination; Enoxaparin; Factor VII; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Stents; Tirofiban; Tyrosine; Vascular Patency | 2002 |
Vertebrobasilar thrombolysis with intravenous tirofiban: case report.
Topics: Aged; Arterial Occlusive Diseases; Fibrinolytic Agents; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine; Vertebrobasilar Insufficiency | 2002 |